Key result
Empagliflozin provides early clinical benefit in patients with heart failure with preserved ejection fraction, who face a 50% 6-month readmission and 20-30% 1-year mortality risk.
Why the study?
Patients with chronic HF are at high risk for adverse outcomes, with high post-hospitalization readmission and mortality rates.
Key points are not available for this paper at this time.
High post-discharge HF risks highlight need for better strategies; leaves open optimal interventions to reduce readmission and mortality.
Patients with chronic heart failure (HF) are at a high risk for adverse outcomes and once hospitalized, the risk for readmission is 20-25 at 1 month and 50% at 6 months, with a 1-year post-discharge mortality rate ranging between 20% and 30%.
No takes yet. Share an insight, caveat, or question.
Butler et al. (2022) studied this question. Empagliflozin provides early clinical benefit in patients with heart failure with preserved ejection fraction, who face a 50% 6-month readmission and 20-30% 1-year mortality risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: